Dbil5 Inhibitors
Dbil5, predicted to possess fatty-acyl-CoA binding and lipid binding activities, plays a role in cytoplasmic lipid metabolism. While direct inhibitors of Dbil5 are not identified, several chemicals with known inhibitory effects on key enzymes and pathways associated with lipid metabolism are considered. These compounds indirectly impact Dbil5 by modulating the availability of fatty-acyl-CoA, thus influencing lipid binding activity and related cellular functions.Etomoxir and Trimetazidine inhibit carnitine palmitoyltransferase 1 (CPT-1) and 3-ketothiolase, respectively, disrupting fatty acid oxidation and affecting the pool of fatty-acyl-CoA. Perhexiline inhibits mitochondrial CPT-1, while Ranolazine targets late sodium current, both indirectly altering fatty-acyl-CoA availability. Etofibrate and Bezafibrate modulate peroxisome proliferator-activated receptor alpha (PPAR-alpha), impacting lipid metabolism and indirectly influencing Dbil5. Malonyl-CoA inhibits CPT-1, affecting fatty acid transport into mitochondria. 5-(Tetradecyloxy)-2-furoic acid inhibits peroxisomal beta-oxidation, while Sodium oligomycin disrupts ATP synthase, impacting energy metabolism.
Carnitine inhibits fatty acid oxidation by preventing fatty acyl-carnitine formation, influencing fatty-acyl-CoA levels. Ranunculin inhibits fatty acid beta-oxidation, and Triclosan inhibits enoyl-acyl carrier protein reductase, both affecting lipid metabolism and indirectly influencing Dbil5. Understanding the interplay between these inhibitors and Dbil5 sheds light on the intricate regulation of cytoplasmic lipid metabolism, providing valuable insights for strategies targeting lipid-related pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $151.00 $506.00 | 3 | |
Inhibits carnitine palmitoyltransferase 1 (CPT-1), hindering fatty acid oxidation. Its indirect impact on Dbil5 involves disrupting the supply of fatty-acyl-CoA, potentially influencing downstream processes associated with lipid binding activity. | ||||||
Trimetazidine Dihydrochloride | 13171-25-0 | sc-220334 | 10 mg | $213.00 | ||
Inhibits 3-ketothiolase, disrupting fatty acid beta-oxidation. Its indirect inhibition of Dbil5 involves modulating the availability of fatty-acyl-CoA, impacting lipid binding activity and potentially influencing cytoplasmic functions related to lipid metabolism. | ||||||
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $188.00 | ||
Inhibits mitochondrial carnitine palmitoyltransferase 1 (mCPT-1), disrupting fatty acid oxidation. Its indirect influence on Dbil5 involves altering the pool of fatty-acyl-CoA, potentially influencing lipid binding activity and cytoplasmic functions related to lipid metabolism. | ||||||
Ranolazine | 95635-55-5 | sc-212769 | 1 g | $109.00 | 3 | |
Inhibits fatty acid oxidation by targeting late sodium current. Its indirect modulation of Dbil5 involves altering fatty-acyl-CoA availability, potentially influencing lipid binding activity and cytoplasmic functions associated with lipid metabolism. | ||||||
Bezafibrate | 41859-67-0 | sc-204650B sc-204650 sc-204650A sc-204650C | 500 mg 1 g 5 g 10 g | $31.00 $46.00 $122.00 $204.00 | 5 | |
Activates PPAR-alpha, impacting lipid metabolism. Its indirect modulation of Dbil5 involves altering the expression of proteins associated with lipid binding activity and influencing cytoplasmic functions related to lipid metabolism. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits CPT-1, hindering fatty acid transport into mitochondria. Its indirect inhibition of Dbil5 involves disrupting fatty acid oxidation, potentially influencing lipid binding activity and cytoplasmic functions related to lipid metabolism. | ||||||
TOFA (5-(Tetradecyloxy)-2-furoic acid) | 54857-86-2 | sc-200653 sc-200653A | 10 mg 50 mg | $97.00 $374.00 | 15 | |
Inhibits peroxisomal beta-oxidation, impacting lipid metabolism. Its indirect influence on Dbil5 involves modulating the levels of fatty-acyl-CoA, potentially affecting lipid binding activity and cytoplasmic functions associated with lipid metabolism. | ||||||
Oligomycin | 1404-19-9 | sc-203342 sc-203342C | 10 mg 1 g | $149.00 $12495.00 | 18 | |
Inhibits ATP synthase, affecting energy metabolism. Its indirect impact on Dbil5 involves altering the availability of ATP, potentially influencing cytoplasmic functions related to lipid binding activity and lipid metabolism. | ||||||
L-Carnitine | 541-15-1 | sc-205727 sc-205727A sc-205727B sc-205727C | 1 g 5 g 100 g 250 g | $23.00 $34.00 $79.00 $179.00 | 3 | |
Inhibits fatty acid oxidation by preventing fatty acyl-carnitine formation. Its indirect modulation of Dbil5 involves influencing the availability of fatty-acyl-CoA, potentially impacting lipid binding activity and cytoplasmic functions associated with lipid metabolism. | ||||||
Triclosan | 3380-34-5 | sc-220326 sc-220326A | 10 g 100 g | $141.00 $408.00 | ||
Inhibits enoyl-acyl carrier protein reductase, affecting fatty acid synthesis. Its indirect impact on Dbil5 involves altering the levels of fatty-acyl-CoA, potentially influencing lipid binding activity and cytoplasmic functions associated with lipid metabolism. | ||||||